Literature DB >> 9700129

Inhibitory effect of pulmonary surfactant proteins A and D on allergen-induced lymphocyte proliferation and histamine release in children with asthma.

J Y Wang1, C C Shieh, P F You, H Y Lei, K B Reid.   

Abstract

The role of pulmonary surfactant proteins in the pathogenesis of airway inflammation and the impact on asthma has not been elucidated. This study was designed to examine the effect of surfactant proteins A (SP-A) and D (SP-D) on phytohemagglutinin- (PHA) and mite allergen Dermatophagoides pteronyssinus (Der p)-induced histamine release and the proliferation of peripheral blood mononuclear cells (PBMC) in children with asthma in stable condition (n = 21), asthmatic children during acute attacks (n = 9), and age-matched control subjects (n = 7). The results show that SP-A and SP-D were able to reduce the incorporation of [3H]thymidine into PBMC in a dose-dependent manner. In addition to the intact, native SP-A and SP-D proteins, a recombinant peptide composed of the neck and carbohydrate recognition domain (CRD) of SP-D [SP-D(N/CRD)] was also found to have the same suppressive effect on lymphocyte proliferation. This effect was abolished by the presence of 100 mM mannose (for SP-A) or maltose (for SP-D) in the culture medium, which suggested that the CRD regions of SP-A and SP-D may interact with the carbohydrate structures on the surface molecules of lymphocytes. The inhibitory effects of surfactant proteins on PHA- and Der p-stimulated lymphocyte responses were observed in stable asthmatic children and age-matched control subjects, while only a mild suppression (< 25%) was seen in activated lymphocytes derived from asthmatic children with acute attacks. SP-A and SP-D were also found to inhibit allergen-induced histamine release, in a dose-dependent manner, in the diluted whole blood of asthmatic children. We conclude that both SP-A and SP-D can inhibit histamine release in the early phase of allergen provocation and suppress lymphocyte proliferation in the late phase of bronchial inflammation, the two essential steps in the development of asthmatic symptoms. It appears that SP-A and SP-D may be protective against the pathogenesis of asthma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700129     DOI: 10.1164/ajrccm.158.2.9709111

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  30 in total

1.  Identification of the surfactant protein A receptor 210 as the unconventional myosin 18A.

Authors:  Ching-Hui Yang; Jacek Szeliga; Jeremy Jordan; Shawn Faske; Zvjezdana Sever-Chroneos; Bre Dorsett; Robert E Christian; Robert E Settlage; Jeffrey Shabanowitz; Donald F Hunt; Jeffrey A Whitsett; Zissis C Chroneos
Journal:  J Biol Chem       Date:  2005-08-08       Impact factor: 5.157

Review 2.  Innate immune responses to environmental allergens.

Authors:  Henk F Kauffman
Journal:  Clin Rev Allergy Immunol       Date:  2006-04       Impact factor: 8.667

Review 3.  Therapeutic use of surfactant components in allergic asthma.

Authors:  Veit J Erpenbeck; Norbert Krug; Jens M Hohlfeld
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-15       Impact factor: 3.000

4.  Surfactant protein A is defective in abrogating inflammation in asthma.

Authors:  Ying Wang; Dennis R Voelker; Njira L Lugogo; Guirong Wang; Joanna Floros; Jennifer L Ingram; Hong Wei Chu; Tony D Church; Pitchaimani Kandasamy; Daniel Fertel; Jo Rae Wright; Monica Kraft
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-07-22       Impact factor: 5.464

5.  Surfactant protein D-mediated decrease of allergen-induced inflammation is dependent upon CTLA4.

Authors:  Ko-Wei Lin; Kai Yu Jen; Carlos Jose Suarez; Erika C Crouch; David L Perkins; Patricia W Finn
Journal:  J Immunol       Date:  2010-04-30       Impact factor: 5.422

Review 6.  The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections.

Authors:  SeungHye Han; Rama K Mallampalli
Journal:  Ann Am Thorac Soc       Date:  2015-05

7.  Intranasal delivery of a truncated recombinant human SP-D is effective at down-regulating allergic hypersensitivity in mice sensitized to allergens of Aspergillus fumigatus.

Authors:  P Strong; K B M Reid; H Clark
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

8.  Lung effector memory and activated CD4+ T cells display enhanced proliferation in surfactant protein A-deficient mice during allergen-mediated inflammation.

Authors:  Amy M Pastva; Sambuddho Mukherjee; Charles Giamberardino; Bethany Hsia; Bernice Lo; Gregory D Sempowski; Jo Rae Wright
Journal:  J Immunol       Date:  2011-01-21       Impact factor: 5.422

9.  Surfactant protein D alters allergic lung responses in mice and human subjects.

Authors:  Eric B Brandt; Melissa K Mingler; Michelle D Stevenson; Ning Wang; Gurjit K Khurana Hershey; Jeffrey A Whitsett; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2008-03-19       Impact factor: 10.793

10.  An antibody against the surfactant protein A (SP-A)-binding domain of the SP-A receptor inhibits T cell-mediated immune responses to Mycobacterium tuberculosis.

Authors:  Buka Samten; James C Townsend; Zvjezdana Sever-Chroneos; Virginia Pasquinelli; Peter F Barnes; Zissis C Chroneos
Journal:  J Leukoc Biol       Date:  2008-05-01       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.